Skip to contentC
China Pharma Holdings, Inc.
C
CPHIChina Pharma Holdings, Inc. Q4 2018 · 10-K
derived · Computed from the longer spans the company filed.
Revenue$3.24M$3.24Mderived−15.7% vs Q4 2017 Net Income-$7.59M-$7.59MderivedN/M vs Q4 2017 EPS, diluted—
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
China Pharma Holdings, Inc. · CIK 1106644 · Engraved from SEC EDGAR
Not derived. Share counts vary by quarter.
Gross Profitderived-$170,878N/M Operating Incomederived-$7,510,890N/M Operating Cash Flowderived$249,304−73.4% Free Cash Flowderived$231,491−73.3% Margins · derivedGross margin-5.3%−23.0 pt vs Q4 2017
Operating margin-231.6%+124.2 pt vs Q4 2017
Net margin-234.1%+125.2 pt vs Q4 2017
ended Dec 31, 2018 · filed Mar 28, 2019 · 87 d after period end